Breast cancer survivors who underwent chemotherapy or hormone therapy were found to be more likely to have a higher symptom burden and lower overall sense of well-being than noncancer counterparts.
An analysis of the results of the phase III PANTHER trial showed that a combination of tailored dose-dense adjuvant chemotherapy and trastuzumab decreased the relative risk of relapse for patients with HER2-positive breast cancer.
A phase I study showed brentuximab vedotin combined with a standard chemotherapy regimen of mitoxantrone, etoposide, and cytarabine may be safe and well tolerated in patients with relapsed/refractory acute myeloid leukemia.
The use of common heart drugs in conjunction with cancer therapy led to reduced cardiotoxicity in patients with breast and hematological cancers.
A research team from the Mayo clinic verified the known risk factors for endometrial cancer, while identifying a possible microbiome signature associated with the disease.
The use of aspirin 3 or more times a week was associated with a reduction in all-cause, cancer, gastrointestinal cancer, and colorectal cancer mortality in adults 65 and over, according to a study published in JAMA Network Open.
Integrated analyses showed entrectinib to be both effective and well tolerated in patients with rare ROS1 and NTRK gene fusions.
The updated and expanded NCCN guidelines broaden the testing criteria, while clarifying who should be tested for genetic mutations.
Patients with metastatic non-small cell lung cancer who harbor HER2-mutations may develop brain metastases more frequently during treatment.